Butorphanol agonist effects and acute physical dependence in opioid abusers: comparison with morphine

被引:28
作者
Greenwald, MK [1 ]
Stitzer, ML [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Behav Pharmacol Res Unit, Baltimore, MD 21205 USA
关键词
narcotic dependence; opioid withdrawal; morphine; butorphanol; naloxone; human drug abusers;
D O I
10.1016/S0376-8716(98)00104-5
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
This study compared the direct effects and acute physical dependence of butorphanol and morphine, opioids with differing actions at mu versus kappa receptors. Six non-dependent heroin-using volunteers were exposed to six conditions in a within-subject, Latin square design using double-blind procedures. In each session, agonist effects of single i.m. injections of butorphanol (3 and 6 mg/70 kg), morphine (15 and 30 mg/70 kg), lorazepam (4 mg/70 kg) or saline were evaluated. Butorphanol and morphine produced effects of comparable magnitude on miosis and reports of 'any drug effect'. Volunteers reported dysphoria, confusion and sedation after butorphanol, subjective effects that overlapped with those of lorazepam, whereas morphine produced euphoria and stimulation. Acute physical dependence (i.e, precipitated withdrawal responses to naloxone 10 mg/70 kg i.m. administered 6 h after each treatment) significantly increased after 30 mg/70 kg morphine but not after butorphanol treatments. These differences in naloxone sensitivity are likely due to differences in opioid receptor (mu versus kappa) activity, affinity and efficacy of these compounds. Pharmacological ramifications of these results are discussed. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:17 / 30
页数:14
相关论文
共 86 条
[61]  
PRESTON KL, 1994, J PHARMACOL EXP THER, V271, P48
[62]   DISCRIMINATION OF BUTORPHANOL AND NALBUPHINE IN OPIOID-DEPENDENT HUMANS [J].
PRESTON, KL ;
BIGELOW, GE ;
LIEBSON, IA .
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1990, 37 (03) :511-522
[63]  
PRESTON KL, 1989, J PHARMACOL EXP THER, V250, P184
[64]  
PRESTON KL, 1988, J PHARMACOL EXP THER, V246, P441
[65]   PSYCHOPHARMACOLOGY AND ABUSE POTENTIAL OF TRANSNASAL BUTORPHANOL [J].
PRESTON, KL ;
SULLIVAN, JT ;
TESTA, M ;
JASINSKI, DR .
DRUG AND ALCOHOL DEPENDENCE, 1994, 35 (02) :159-167
[66]   ABUSE LIABILITY STUDIES OF OPIOID AGONIST-ANTAGONISTS IN HUMANS [J].
PRESTON, KL ;
JASINSKI, DR .
DRUG AND ALCOHOL DEPENDENCE, 1991, 28 (01) :49-82
[67]   DIURETIC EFFECTS, PHARMACOKINETICS, AND SAFETY OF A NEW CENTRALLY ACTING KAPPA-OPIOID AGONIST (CI-977) IN HUMANS [J].
REECE, PA ;
SEDMAN, AJ ;
ROSE, S ;
WRIGHT, DS ;
DAWKINS, R ;
RAJAGOPALAN, R .
JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 34 (11) :1126-1132
[68]  
Reisine T., 1996, GOODMAN GILMANS PHAR, P521
[69]  
RIMOY GH, 1994, EUR J CLIN PHARMACOL, V46, P203
[70]  
SCHAEFER GJ, 1978, J PHARMACOL EXP THER, V205, P291